Literature DB >> 7126427

Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality.

T J Anderson, D J Ferguson, G M Raab.   

Abstract

Morphological identification of cell multiplication (mitosis) and cell deletion (apoptosis) within the lobules of the "resting" human breast is used to assess the response of the breast parenchyma to the menstrual cycle. The responses are shown to have a biorhythm in phase with the menstrual cycle, with a 3-day separation of the mitotic and apoptotic peaks. The study fails to demonstrate significant differences in the responses between groups defined according to parity, contraceptive-pill use or presence of fibroadenoma. However, significant differences are found in the apoptotic response according to age and laterality. The results highlight the complexity of modulating influences on breast parenchymal turnover in the "resting" state, and prompt the investigation of other factors as well as steroid hormones and prolactin in the promotion of mitosis. The factors promoting apoptosis in the breast are still not clear.

Entities:  

Keywords:  Age Factors; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods; Demographic Factors; Family Planning; Fertility; Fertility Measurements; Histology; Mammary Gland Effects; Menstrual Cycle; Menstruation; Oral Contraceptives; Parity; Physiology; Population; Population Characteristics; Population Dynamics; Reproduction; Reproductive Control Agents

Mesh:

Substances:

Year:  1982        PMID: 7126427      PMCID: PMC2011125          DOI: 10.1038/bjc.1982.213

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Response to epidermal growth factors of cultured human mammary epithelial cells from benign tumours.

Authors:  M G Stoker; D Pigott; J Taylor-Papadimitriou
Journal:  Nature       Date:  1976 Dec 23-30       Impact factor: 49.962

2.  Atrophy and apoptosis in the cyclical human endometrium.

Authors:  D Hopwood; D A Levison
Journal:  J Pathol       Date:  1976-07       Impact factor: 7.996

3.  Serum estradiol in women ingesting combination oral contraceptive steroids.

Authors:  D R Mishell; I H Thorneycroft; R M Nakamura; Y Nagata; S C Stone
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

4.  Breast cancer, pregnancy, and the pill.

Authors:  J O Drife
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-19

5.  Ultrastructural observations on cell death by apoptosis in the "resting" human breast.

Authors:  D J Ferguson; T J Anderson
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

6.  Prolactin levels during the menstrual cycle.

Authors:  P Franchimont; C Dourcy; J J Legros; A Reuter; Y Vrindts-Gevaert; J R Van Cauwenberge; U Gaspard
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

7.  Homologous radioimmunoassay for human epidermal growth factor (urogastrone).

Authors:  G E Dailey; J W Kraus; D N Orth
Journal:  J Clin Endocrinol Metab       Date:  1978-06       Impact factor: 5.958

8.  Inadequate corpus luteal function in women with benign breast diseases.

Authors:  L R Sitruk-ware; N Sterkers; I Mowszowicz; P Mauvais-Jarvis
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

9.  Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones.

Authors:  J S Meyer
Journal:  Hum Pathol       Date:  1977-01       Impact factor: 3.466

10.  Human epidermal growth factor: isolation and chemical and biological properties.

Authors:  S Cohen; G Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  47 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Establishing a framework for the functional mammary gland: from endocrinology to morphology.

Authors:  Russell C Hovey; Josephine F Trott; Barbara K Vonderhaar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

Review 3.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

4.  Scar and non-scar ductal cancer of the female breast. Observations on patient age, tumour size, and hormone receptors.

Authors:  S Partanen; H Hyvärinen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 5.  [Anatomy of the breast].

Authors:  W Böcker; D Hungermann; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

6.  Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies.

Authors:  L Bernstein; J M Yuan; R K Ross; M C Pike; R Hanisch; R Lobo; F Stanczyk; Y T Gao; B E Henderson
Journal:  Cancer Causes Control       Date:  1990-07       Impact factor: 2.506

7.  Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.

Authors:  J J Going; T J Anderson; S Battersby; C C MacIntyre
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

Review 8.  Hormonal regulation of the immune microenvironment in the mammary gland.

Authors:  Eleanor F Need; Vahid Atashgaran; Wendy V Ingman; Pallave Dasari
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-07-04       Impact factor: 2.673

Review 9.  The contraceptive pill and breast cancer in young women.

Authors:  J O Drife
Journal:  BMJ       Date:  1989-05-13

Review 10.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.